Shares of Puma Biotechnology (NASDAQ: PBYI), a biopharmaceutical company marketing one cancer drug, fell 12.3% in mid-day trading on Monday after the company announced a new marketing partnership. Investors unimpressed by the terms pushed the stock 8.1% lower to end the session.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,